GlaxoSmithKline, Innoviva Asthma Inhaler Meets Primary Endpoint in Trial
02 Maggio 2019 - 06:59PM
Dow Jones News
By Adria Calatayud
GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) said
Thursday that their Trelegy Ellipta inhaler, which treats patients
living with uncontrolled asthma, met the primary endpoint in a
phase 3 study.
The pharmaceutical companies said the study showed a
statistically significant improvement in lung function at 24 weeks
of once-daily treatment with Trelegy Ellipta compared with other
medication.
However, the drug didn't achieve a statistically significant
reduction in the annualized rate of asthma exacerbations, which was
the secondary endpoint of the trial, the companies said.
Write to Adria Calatayud at
adria.calatayudvaello@dowjones.com
(END) Dow Jones Newswires
May 02, 2019 12:44 ET (16:44 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2023 a Mar 2024